Dashboard
1
Poor long term growth as Net Sales has grown by an annual rate of 0.25% and Operating profit at -13.16% over the last 5 years
2
The company has declared Positive results for the last 3 consecutive quarters
3
With ROE of 11.11%, it has a very attractive valuation with a 2.62 Price to Book Value
4
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
CNY 11,374 Million (Mid Cap)
24.00
NA
2.14%
-0.06
11.11%
2.51
Revenue and Profits:
Net Sales:
813 Million
(Quarterly Results - Mar 2026)
Net Profit:
67 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-15.31%
0%
-15.31%
6 Months
-20.42%
0%
-20.42%
1 Year
-6.12%
0%
-6.12%
2 Years
-5.9%
0%
-5.9%
3 Years
-21.84%
0%
-21.84%
4 Years
-23.15%
0%
-23.15%
5 Years
-61.71%
0%
-61.71%
Xiamen Kingdomway Group Co. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.25%
EBIT Growth (5y)
-13.16%
EBIT to Interest (avg)
19.01
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
-0.03
Sales to Capital Employed (avg)
0.60
Tax Ratio
21.11%
Dividend Payout Ratio
71.34%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
15.55%
ROE (avg)
13.09%
Valuation key factors
Factor
Value
P/E Ratio
24
Industry P/E
Price to Book Value
2.62
EV to EBIT
20.32
EV to EBITDA
14.61
EV to Capital Employed
2.63
EV to Sales
3.31
PEG Ratio
0.21
Dividend Yield
2.15%
ROCE (Latest)
12.95%
ROE (Latest)
11.11%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
813.40
761.10
6.87%
Operating Profit (PBDIT) excl Other Income
105.40
44.10
139.00%
Interest
15.50
25.40
-38.98%
Exceptional Items
-0.50
-54.40
99.08%
Consolidate Net Profit
67.10
-33.00
303.33%
Operating Profit Margin (Excl OI)
129.50%
-14.30%
14.38%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 6.87% vs -13.10% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 303.33% vs -128.87% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
3,360.60
3,236.20
3.84%
Operating Profit (PBDIT) excl Other Income
677.90
661.90
2.42%
Interest
61.40
31.50
94.92%
Exceptional Items
-96.50
-12.90
-648.06%
Consolidate Net Profit
320.60
367.00
-12.64%
Operating Profit Margin (Excl OI)
136.60%
138.80%
-0.22%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.84% vs 4.52% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -12.64% vs 32.87% in Dec 2024
About Xiamen Kingdomway Group Co. 
Xiamen Kingdomway Group Co.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






